NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE (NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE).
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
| Metabolism | Naphazoline: Primarily hepatic metabolism via monoamine oxidase (MAO); Pheniramine: Hepatic metabolism via cytochrome P450 (CYP) enzymes, including CYP2D6 and CYP3A4. |
| Excretion | Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination. |
| Half-life | Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing. |
| Protein binding | Naphazoline: Approximately 25% bound to plasma proteins (albumin). Pheniramine: Approximately 70-80% bound to plasma proteins (albumin). |
| Volume of Distribution | Naphazoline: Vd ~1.5 L/kg, indicating moderate distribution into tissues. Pheniramine: Vd ~4-6 L/kg, indicating extensive tissue distribution, including CNS. |
| Bioavailability | Ophthalmic: Low systemic bioavailability due to small dose and local administration; systemic absorption <1% of applied dose. Not intended for systemic use. |
| Onset of Action | Ophthalmic: Onset within 10 minutes (naphazoline vasoconstriction); pheniramine antihistamine effect begins within 15-30 minutes. |
| Duration of Action | Ophthalmic: Duration of vasoconstriction 2-6 hours; antihistamine effect may last 4-6 hours. Clinical use: Twice daily or as needed for relief of ocular itching and redness. |
| Molecular Weight | Naphazoline hydrochloride: 246.74 Da; Pheniramine maleate: 401.47 Da. Combined product: weighted average not applicable; each drug reported separately. |
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for topical use; systemic absorption minimal |
| Liver impairment | No dose adjustment required for topical use; systemic absorption minimal |
| Pediatric use | Children under 6 years: not recommended. Children 6-12 years: 1 drop or spray in each nostril every 6-8 hours, not to exceed 3 days |
| Geriatric use | Use with caution; avoid extended use (>3-5 days) due to increased risk of rhinitis medicamentosa and rebound congestion |
| 1st trimester | Avoid use in first trimester unless clearly needed. Limited human data; animal studies not available. Potential risk of vasoconstriction affecting placental perfusion. |
| 2nd trimester | Use only if potential benefit justifies potential risk to fetus. May cause uterine contractions and reduced placental blood flow due to alpha-adrenergic effects. |
| 3rd trimester | Avoid use near term. Naphazoline may cause fetal bradycardia and hypoxia; pheniramine may precipitate premature uterine contractions. |
Clinical note
Comprehensive clinical and safety monograph for NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE (NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE).
| Placental transfer | Naphazoline is a small molecule and likely crosses placenta; pheniramine also crosses. Both drugs have molecular weights <500 Da, suggesting placental transfer. Degree of transfer not well quantified. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Narrow-angle glaucomaHypersensitivity to naphazoline or pheniramineConcurrent use with MAO inhibitors or within 14 daysSevere hypertension or coronary artery diseaseChildren under 6 years (due to systemic absorption risks)
| Precautions | Do not exceed recommended dosage or frequency of use, Prolonged use may cause rebound conjunctival hyperemia, Use caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or narrow-angle glaucoma, May cause pupillary dilation leading to angle-closure glaucoma in susceptible patients, Do not use in patients with narrow-angle glaucoma, Discontinue if eye pain, vision changes, or persistent redness occurs |
| Food/Dietary | No known food interactions. Avoid alcohol as it may increase risk of dizziness or drowsiness from pheniramine. |
Loading safety data…
| Small amounts of both drugs may be excreted into breast milk. Naphazoline levels are low due to poor oral bioavailability; pheniramine may cause irritability or drowsiness in the infant. Use caution, especially in premature infants or those with compromised respiratory function. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Naphazoline is an imidazoline derivative vasoconstrictor; no adequate studies in pregnant women. Topical ocular use may produce systemic absorption, but risk is low with short-term use. Pheniramine is an alkylamine antihistamine; no teratogenic effects reported in animal studies. Avoid during first trimester if possible. Both drugs are FDA Pregnancy Category C. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate due to vasoconstrictive effects of naphazoline. Observe for signs of systemic toxicity (e.g., hypertension, tachycardia). Fetal monitoring not routinely required, but consider if maternal toxicity occurs. |
| Fertility Effects | No known effects of naphazoline on fertility. Pheniramine: No reproductive toxicity reported. No clinical data on impact of this combination on fertility. |
| Clinical Pearls | Naphazoline is an imidazoline sympathomimetic with rapid vasoconstriction; pheniramine is an alkylamine antihistamine. Onset of decongestant effect within 5-10 minutes, duration 4-6 hours. Avoid in patients with narrow-angle glaucoma, cardiovascular disease, or hypertension. Prolonged use (>3-5 days) may cause rebound congestion (rhinitis medicamentosa). Use with caution in children, elderly, and those with hyperthyroidism. |
| Patient Advice | Do not use for more than 3-5 consecutive days to avoid rebound nasal congestion. · Shake bottle well before use. Tilt head back, administer drops without touching tip to nose. · Avoid getting solution in eyes; if contact occurs, rinse with water for 15 minutes. · May cause temporary stinging, burning, or sneezing after application. · Do not use if you have heart disease, high blood pressure, glaucoma, or difficulty urinating due to enlarged prostate without consulting a doctor. · Stop use and consult doctor if symptoms persist for more than 3 days or worsen. · Keep out of reach of children; overdose may cause serious effects like sedation or low blood pressure. |